Point72 Asset Management
TVRD

Point72 Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Point72 Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-694
Closed -$385K – 1092
2017
Q2 		$385K Sell
694
-695
-50% -$441K ﹤0.01% 778
2017
Q1 		$920K Buy
+1,389
New +$742K 0.01% 745

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management's TVRD Position: Q4 2023 in Review

Point72 Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 3 shares — an estimated $195 sold.

Point72 Asset Management first reported a position in TVRD in Q2 2015 and held it in 12 quarters. The position peaked at $8.94M in Q4 2015. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Point72 Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 3 Tvardi Therapeutics shares in Q4 2023, an estimated $195.
  • Point72 Asset Management first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 12 quarters.
  • Point72 Asset Management's Tvardi Therapeutics position peaked at $8.94M in Q4 2015.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.